Kelly Ross, MD
Hematology & Oncology · Pittsburgh, PANPI 1790004539
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,500 of the $14,311 with a category attached, or 73.4%. ADC Therapeutics America, Inc. accounts for 79.9% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $11,576, more than ten times the $105 reported in 2019.
Across 23 payments — averaging $622.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- GSK$225
- Incyte Corporation$220
- Bristol Myers Squibb$78
- Medtronic$43
- plus $74 from 4 others
Across 64 payments — averaging $4214.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$127K
- Astellas Pharma Global Development$62K
- Takeda Pharmaceuticals U.S.A., Inc.$51K
- Daiichi Sankyo Inc.$14K
- AbbVie$12K
- Pharmacyclics LLC, An Abbvie Company$3K
What the payments were for
- Consulting fees$2,42517%
- Speaking & faculty fees$10,50073%
- Travel & lodging$4703%
- Food & beverage$8506%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 10 | $11,438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $2,233 |
| GSK | 2 | $225 |
| Incyte Corporation | 2 | $220 |
| Bristol Myers Squibb | 1 | $78 |
| Medtronic | 1 | $43 |
| AstraZeneca | 1 | $22 |
| Exact Sciences | 1 | $18 |
| Merck | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,311 in reported general payments places this provider in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 53 | $805,422 |
| PromactaEltrombopag Olamine | 29 | $669,643 |
| RevlimidLenalidomide | 41 | $655,815 |
| PomalystPomalidomide | 23 | $636,278 |
| Lenalidomide | 44 | $618,424 |
| JakafiRuxolitinib Phosphate | 35 | $617,028 |
| BrukinsaZanubrutinib | 25 | $372,934 |
| VenclextaVenetoclax | 31 | $322,437 |
| NinlaroIxazomib Citrate | 14 | $181,817 |
| CalquenceAcalabrutinib Maleate | 11 | $169,361 |
| Imatinib Mesylate | 40 | $79,465 |
| Atovaquone | 29 | $18,998 |
| Posaconazole | 12 | $12,463 |
| Tacrolimus | 24 | $3,004 |
| Acyclovir | 169 | $1,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $78 | $655,81541 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $15 | $636,27823 claims |
| Incyte CorporationJakafi | $220 | $617,02835 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $2,233 | $181,81714 claims |
| AstraZenecaCalquence | $22 | $169,36111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.